Kiran Farheen, MD
Rheumatology · Katy, TXNPI 1255594446
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), consulting fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.1%.
Across 472 payments — averaging $40.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Lilly USA, LLC$3K
- Pfizer$3K
- Amgen$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Fresenius Kabi USA, LLC$2K
- plus $5K from 28 others
Across 92 payments — averaging $7460.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$211K
- E.r. Squibb & Sons, L.L.C.$194K
- GSK$123K
- Novartis$78K
- AbbVie$36K
- Dr.reddy's Laboratories,inc.$23K
- plus $21K from 1 others
What the payments were for
- Consulting fees$9,16049%
- Food & beverage$9,65151%
- Education$700%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 44 | $3,418 |
| Lilly USA, LLC | 27 | $2,722 |
| Pfizer | 53 | $2,648 |
| Amgen(2 entities) | 115 | $1,997 |
| E.r. Squibb & Sons, L.L.C. | 15 | $1,608 |
| Fresenius Kabi USA, LLC | 5 | $1,506 |
| AbbVie | 57 | $1,198 |
| Novartis | 31 | $782 |
| AstraZeneca(2 entities) | 23 | $613 |
| UCB, Inc. | 19 | $399 |
| Mallinckrodt Hospital Products Inc. | 7 | $293 |
| GSK | 15 | $259 |
| Tersera Therapeutics LLC | 9 | $218 |
| Aurinia Pharma U.S., Inc. | 11 | $211 |
| Sanofi | 3 | $175 |
| Sobi, Inc | 1 | $135 |
| ANI Pharmaceuticals, Inc. | 5 | $102 |
| Bristol Myers Squibb | 4 | $75 |
| Mallinckrodt Enterprises LLC | 3 | $69 |
| Boehringer Ingelheim | 3 | $68 |
| Scilex Pharmaceuticals Inc. | 3 | $59 |
| Fidia Pharma USA Inc. | 4 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Bioventus LLC | 2 | $32 |
| Alvogen Inc | 1 | $25 |
| Radius Health, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Medexus Pharma, Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Organon | 1 | $12 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,881 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 53 | $388,856 |
| RinvoqUpadacitinib | 46 | $293,410 |
| Humira(Cf) PenAdalimumab | 31 | $250,346 |
| EnbrelEtanercept | 28 | $203,438 |
| SimponiGolimumab | 32 | $190,547 |
| XeljanzTofacitinib Citrate | 33 | $178,280 |
| Cosentyx Sensoready PenSecukinumab | 21 | $173,980 |
| Cimzia (2 Pack)Certolizumab Pegol | 20 | $112,757 |
| RasuvoMethotrexate/Pf | 13 | $13,982 |
| Leflunomide | 189 | $10,671 |
| Hydroxychloroquine Sulfate | 185 | $8,719 |
| MethotrexateMethotrexate Sodium | 284 | $6,991 |
| Mycophenolate Mofetil | 20 | $3,271 |
| Colchicine | 73 | $3,117 |
| Prednisone | 400 | $2,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,198 | $293,41046 claims |
| AmgenEnbrel | $1,997 | $203,43828 claims |
| Johnson & JohnsonSimponi | $3,418 | $190,54732 claims |
| PfizerXeljanz | $2,648 | $178,28033 claims |
| UCB, Inc.Cimzia (2 Pack) | $399 | $112,75720 claims |
| Medexus Pharma, Inc.Rasuvo | $14 | $13,98213 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $59 | $3,11773 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Katy
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.